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Abstract: A series of 4-arylthiosemicarbazides substituted at the N1 position with a  
5-membered heteroaryl ring was synthesized and evaluated in vitro for T. gondii inhibition 
proliferation and host cell cytotoxicity. At non-toxic concentrations for the host cells all 
studied compounds displayed excellent anti-parasitic effects when compared to 
sulfadiazine, indicating a high selectivity of their anti-T. gondii activity. The differences in 
bioactivity investigated by DFT calculations suggest that the inhibitory activity of 4-aryl-
thiosemicarbazides towards T. gondii proliferation is connected with the electronic 
structure of the molecule. Further, these compounds were tested as potential antibacterial 
agents. No growth-inhibiting effect on any of the test microorganisms was observed for all 
the compounds, even at high concentrations. 
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1. Introduction 
Toxoplasma gondii (T. gondii) is a worldwide distributed protozoan responsible for toxoplasmosis, 
one of the most prevalent parasitic infections in humans [1,2]. Typically, T. gondii infection in 
immunocompetent hosts is minor, self-limiting, and the parasite becomes dormant. However, it can 
have serious effects on immunocompromised individuals, such as HIV-AIDS positive, cancer or organ 
transplant human patients [2,3]. Under such conditions, T. gondii can result in life-threatening 
toxoplasmosis with Toxoplasma encephalitis and other complications (i.a. necrotic lesions within the 
central nervous system or retinochoroiditis) [4,5]. Moreover, women infected with T. gondii for the 
first time during pregnancy will pass the parasite on to the fetus. The estimated incidence of congenital 
toxoplasmosis in Poland was compatible with incidences (1 to 10 per 10,000 live births) reported in 
other European countries, in the United States, or in Japan. Congenital T. gondii infection may result in 
serious neurological and ophthalmic damage to the fetus or even, especially in the first three months of 
the pregnancy, spontaneous abortion. Furthermore, reactivation of undiagnosed congenital toxoplasmosis 
can lead to ocular toxoplasmosis later in life, in many cases causing blindness [6–8]. 
In spite of the severe consequences of toxoplasmosis, the therapy for this disease has not changed in 
the last 20 years. The current treatment involves the use of synergistic combinations of pyrimethamine, 
which inhibits the enzymatic activity of dihydrofolate reductase, and sulfonamides such as trimethoprim-
sulfamethoxazole or sulfadiazine, whose target is dihydropteroate synthetase, supplemented with folinic 
acid [9,10]. The efficacy of this regime is limited, requiring the administration of relatively large amounts 
of drugs. Side effects include hypersensitivity, haematological toxicity, teratogenicity, allergic reactions, 
bone marrow suppression, and the development of resistance [11–15]. Furthermore, this treatment is 
not effective in eliminating the parasite located in the central nervous system [16,17]. An alternative is 
pyrimethamine in conjunction with clindamycin, spiramycin or atovaquone, but these drugs each 
possess their own limitations [8–20]. Thus, limited efficacy and side effects of existing drugs together 
with severe damage caused by T. gondii infection clearly indicates the need for development of new 
non-toxic, well-tolerated, and more efficacious therapeutic agents for controlling and curing toxoplasmosis. 
Recently, Liesen et al. [21] have documented for the first time the anti-T. gondii activity of 
thiosemicarbazide-based compounds. According to the biological results, the tested compounds 
showed better LD50 values for both infected cells and intracellular parasites than the standard drugs 
sulfadiazine and hydroxyurea (see Figure 1). Since that time, no further reports have appeared in the 
literature describing the action thiosemicarbazides against T. gondii. Inspired by those results, efforts 
have been made by our research group to expand these initial findings with further details on  
anti-T. gondii activity of thiosemicarbazides. Herein, we present the outcomes of these investigations, 
as well as the results of subsequent DFT calculations, which allowed us to suggest that inhibitory 
activity of 4-arylthiosemicarbazides towards T. gondii proliferation is connected with the electronic 
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structure of the molecule. In further studies, antibacterial activity of title thiosemicarbazide derivatives 
and inhibitory potency of one selected compound against bacterial type IIA topoisomerases are presented. 
Figure 1. Left: Structures of 4-aryl-1-(4-methyl-1H-imidazole-5-yl)carbonylthiosemicarbazides 
with more potent anti-Toxoplasma gondii activity than the standard drugs sulfadiazine and 
hydroxyurea [21]; and right: Structures of title 4-aryl-1-hetarylcarbonylthiosemicarbazides. 
  
2. Results and Discussion 
2.1. Chemistry 
As mentioned in the Introduction, recently Liesen et al. [21] documented for the first time the  
anti-Toxoplasma gondii activity of four 4-arylthiosemicarbazides with an imidazole ring at the N1 
position (Figure 1). All studied compounds had a range of LD50 values between 0.05–5 mM for 
infected cells and 0.05–1.5 mM for parasites, indicating a more effective action than the standard drugs 
sulfadiazine (LC50 > 10 mM for infected cells, LC50 = 0.5 mM for intracellular parasites) and 
hydroxyurea (LC50 > 10 mM for infected cells, LC50 = 6 mM for intracellular parasites). According to 
the SAR analysis results, the electronic nature of the substituents on the phenyl ring of the 4-aryl-1-(4-
methyl-1H-imidazole-5-yl)carbonylthiosemicarbazides seemed to have a low influence on bioactivity, 
thus indicating the dominant role of the imidazole moiety for modulating the bioactivity of the studied 
compounds. The promising bioassay results inspired us to design a series of 4-arylthiosemicarbazides 
with thiadiazole, thiophene or furan rings at the N1 position. Based on the results presented by Liesen 
et al. [21] we expected that the replacement of the imidazole core in 4-aryl-1-(4-methyl-1H-imidazole-
5-yl)carbonylthiosemicarbazide with a similarly sized five-membered heteroaryl ring would result in 
compounds with a comparable bioactivity profile. The designed thiosemicarbazides presented 
structures similar to those proposed by Liesen et al. [21], with sulphur and oxygen atoms at 
C(=O)NHNHC(=S) core on the same side (Figure 2, left) or on the opposite side of the molecule 
(Figure 2, right), as confirmed by Amber calculations [22]. 
Subsequently, these compounds were synthesized and Scheme 1 shows the synthetic route 
employed for their preparation. As can be seen, a simple synthesis was carried out, starting from the 
commercially available carboxylic acid hydrazides and the appropriate isothiocyanates, in ethanolic 
medium. At the end of the reaction, the isolated thiosemicarbazide derivatives were obtained as 
colourless solids. This procedure was adapted from an article previously reported by Plech et al. [23] 
and gave us satisfactory yields. 
  
R
R = H, OMe, Cl, F
Het
Het = five-membered heterocyclic ring; R = aryl, alkyl
 
R
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Figure 2. Structures of representative 4-aryl-1-(4-methyl-1H-imidazole-5-
yl)carbonylthiosemicarbazides [21] with sulphur and oxygen atoms at C(=O)NHNHC(=S) 
core on the same side (left) or on the opposite side of the molecule (right). 
Scheme 1. Synthetic route for 1,4-disubstituted thiosemicarbazides (series 1–3). 
 
2.2. In Vitro Anti-Toxoplasma gondii Activity of the Title Compounds 
In the next step of our studies, the prepared 1,4-disubstituted thiosemicarbazides (series 1–3) were 
used to assess the inhibition of T. gondii growth in vitro. For this purpose, intracellular parasites 
(tachyzoites) of RH strain were incubated with different concentrations of the thiosemicarbazides 
ranging from 1 to 100 µg/mL. Inhibition of the parasite growth was monitored by measuring the 
specific incorporation of [3H]uracil in the parasite’s nucleic acids. Unfortunately, among the 15 
compounds tested, derivatives 1a–1e, 1k, 1l, 2f, 2i, 2j, and 3h were insoluble under the protocol 
conditions and, consequently, they were eliminated from further experiments. The percentages of the 
parasite growth inhibition in L929 cells by the remaining compounds 1g, 2b, 3d, 3l and the control 




Ri = (1), Me (2), (3)
Rj = Ph (a), 2Me-Ph (b), 2-FPh (c), 2-BrPh (d), 3-MePh (e), 4-MePh (f), 4-FPh (g), 
       4-ClPh (h), 4-BrPh (i), 4-IPh (j), 4-NO2Ph (k), 2,4-diFPh (l), Et (m), C6H11 (n)    
series 1: 1a, 1b, 1c, 1d, 1e, 1g, 1k, 1l, 1m, 1n
series  2: 2b, 2f, 2i, 2j, 2m
series  3: 3d, 3l, 3h    
Ri
Me
Molecules 2014, 19 9930 
 
Table 1. Effect of studied compounds on the intensity of T. gondii proliferation (%) in the L929 host cells. 
Cmpd. No. 
Assay: Concentration [µg/mL] 
IC50 [µg/mL] A. [3H] Uracil Incorporation
B. qRT-PCR 
100 50 10 5 1 
1g 
A. nt 12.62 ± 4.78 * 44.71 ± 16.60 * 74.94 ± 7.00 * 96.14 ± 14.54 33.17 
B. nt 5.00 ± 2.56 * 61.01 ± 11.23 * nt nt nt 
2b 
A. 8.10 ± 2.78 * 58.78 ± 11.49 * 112.25 ± 22.91 * 107.95 ± 24.88 98.24 ± 23.83 59.00 
B. 7.29 ± 1.56 * 41.37 ± 9.98 * nt nt nt nt 
3d 
A. 36.52 ± 5.16 * 63.82 ± 5.32 * 83.84 ± 19.01 84.64 ± 15.68 90.03 ± 14.61 74.93 
B. 25.56 ± 6.32 * 75.13 ± 10.10 * nt nt nt nt 
3l 
A. 37.20 ± 7.47 * 88.34 ± 14.40 * 103.21 ± 19.27 85.76 ± 19.71 84.59 ± 16.61 92.28 
B. 14.08 ± 3.35 * 89.32 ± 15.74 * nt nt nt nt 
sulfadiazine
A. 71.53 ± 8,94 * 78.73 ± 8,29 * 82.14 ± 11,26 79.18 ± 6,29 * 90.37 ± 11,65 * >500 ** 
B. 63.99 ± 10.58 * nt nt nt nt nt 
2m 
A. 57.59 ± 15.02 * 66.49 ± 11.38 * 60.61 ± 9.56 * 75.74 ± 14.62 98.00 ± 19.53 191.04 
B. 53.03 ± 9.87 * 51.03 ± 7.02 * nt nt nt nt 
nt: Not tested, * p < 0.05; to calculate the intensity of T. gondii proliferation compared to the untreated blank, the Equation was used: proliferation (%) = [100 × sample 
OD570 (the mean value of the measured optical density of the 1–100 µg/mL compounds of the test samples / blank OD570. (the mean value of the measured optical density 
of the untreated cells)]. IC50 [µg/mL]: Represents the concentration of tested compounds that was required for 50% of T. gondii proliferation inhibition in vitro.  
** Numerous studies have shown that the drug susceptibility for parasites depended on the host cells used. Using as a model, RH strain and human MRC-5 cells [24,25], 
Vero [26] and HFF [27] as a host normal cells, the IC50 value of sulfadizaine reached from 2.5 to 77 μg/mL compared to human carcinoma HEp-2 and HeLa cells showing 
IC50 values between 600–700 μg/mL and >1000 μg/mL, respectively [28,29]. 
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According to these results, all thiosemicarbazides 1g, 2b, 3d, 3l showed significant and 
reproducible anti-parasitic effects, with the assigned IC50 values 5- to 15-fold lower than those 
observed for sulfadiazine (IC50 > 500 µg/mL). Among them, a derivative with the thiophene ring of 1g 
was found to be the most potent anti-T. gondii agent, with an IC50 of 33.17 µg/mL. When the 
thiophene scaffold was replaced with a similar in size furan moiety, as exemplified by 2b, or a 
thiadiazole core, as exemplified by 3d, 3l, bioactivity was substantially lost. IC50 values determined for 
2b, 3d, 3l, however, were still at least 5-fold lower than the values obtained for sulfadiazine (see A in 
Table 1). High anti-parasitic activity of all selected thiosemicarbazides 1g, 2b, 3d, and 3l was also 
confirmed using a quantitative real-time PCR (qRT-PCR) assay (B in Table 1). 
A preliminary assumption was thus put forward that the presence of both the five-membered hetaryl 
moiety at N1 position and the aryl moiety at N4 position of thiosemicarbazide core are the key 
functionalities required for potent anti-T. gondii activity of thiosemicarbazide-based compounds, 
which may be directly linked with the electronic structure of the molecule. In order to verify the 
preliminary hypothesis, 4-ethyl-1-(thiophen-2-yl)carbonylthiosemicarbazide (1m), 4-cyclohexyl-1-
(thiophen-2-yl)carbonylthiosemicarbazide (1n), and 4-ethyl-1-(2-methylfuran-3-yl)carbonylthio-
semicarbazide (2m) were synthesized and their bioactivity was tested. Unfortunately, derivatives 1m 
and 1n were insoluble under the protocol conditions and, consequently, they were eliminated from 
further experiments. Indeed, the replacement of the ortho-tolyl ring in 2b with the ethyl chain as in 2m 
resulted in a significant loss of bioactivity (IC50 59.00 vs. 191.04 µg/mL, see Table 1 last entry), 
thereby confirming the validity of the aforementioned assumption. The assumption of the existence of 
the relationship between the anti-T. gondii activity of the studied thiosemicarbazides and their 
molecular structure was also confirmed based on DFT calculations. Figure 3 illustrates the electrostatic 
potential mapped on the density surface using the Gaussview program. Neutral fragments are 
characterized by the green color of the surface. The negative charge is represented by red, while the 
positive charge is marked in blue. If compound 1g is excluded from the consideration, the biological 
activity correlates well with the dipole moment of the molecule. In this series it seems that the activity 
depends on the bimodal partial negative charge developed on the carbonyl oxygen and another moiety 
on the same side of the molecule (a sulfur atom in 2b and 3d). Its low value in 3l and lack in 2m may 
be responsible for the lower activity. However, the most active compound 1g is characterized by the 
lowest dipole moment. It contains, however, two partial negative charge centers as the series discussed 
above and an additional such center on the fluorine atom. Comparison of the biological activity of 1g 
and 2m seems to indicate the crucial role of the second negative charge density on the top of the 
molecule on a moiety other than the carbonyl oxygen. Another observation that comes from the 
analysis of the presented structures is that the biological activity is pronounced when the methyl group 
of the five-membered ring is directed away from the carbonyl group. Since the number of compounds 
studied here is limited, the above observations can be treated as initial suggestions only and will be 
used as a guide for synthesis of other compounds in further studies. 
In order to understand the molecular mechanism by which thiosemicarbazides induce their 
inhibitory activity towards T. gondii, the docking studies were carried out. The knowledge of unique 
aspects of T. gondii biochemistry and physiology has led to the identification of seven enzymes, 
essential for the survival, growth, replication, or viability of the microorganism, as reasonable targets 
for anti-Toxoplasma agents. According to the enzymatic studies, purine nucleoside phosphorylase 
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(PNP) [30], adenosine kinase [EC.2.7.1.20] [31], dihydrofolate reductase (DHFR) [32,33], calcium-
dependent protein kinase-1 (TgCDPK1) [34–37], 1-deoxy-D-xylulose-5-phosphate reductoisomerase 
(DXR) [38–40], enoyl reductase (TgENR) [41] were considered as attractive targets for discovering 
selective inhibitors to combat infections caused by this protozoan. Inspired by these results, based on 
the structures deposited in the Protein Data Bank, we analyzed the binding affinity of the title 
thiosemicarbazides with the active sites of aforementioned enzymes, with the exception of the model 
of dihydrofolate reductase (DHFR) binding site (PDB ID 4EIL) that retained several pathologies. The 
docking simulations were performed using the FlexX docking module [42] of the LeadIT environment 
as implemented in the BioSolveITprogram [43]. The total docking and hide scores of the studied 
compounds within the active sites of target enzymes together with H-bonds and close hydrophobic 
interactions are displayed in Table S1 in Supplementary Material. Although no structure-activity 
relationships (SAR) trends were observed when the docking conformations, the scores, and the 
interactions between thiosemicarbazide and residues of the binding site were analyzed in detail, all 
compounds were recognized as potential inhibitors of studied enzymes. To these enzymes, 
ribonucleotide reductase should also be included since this enzyme was identified as molecular target 
for anti-T. gondii activity of thiosemicarbazones—compounds closely related to thiosemicarbazides [21]. 
Of course, these above-mentioned proteins are only a very small cross-section of the potential protein 
targets within T. gondii. Evidently, enzymatic studies are necessary to develop our knowledge of the 
molecular basis of thiosemicarbazide derivatives bioactivity. 
Figure 3. The electrostatic potential surfaces and dipole moments of 1g, 2b, 2m, 3d, and 3l. 
 
1g μ = 1.99 D 2b μ = 8.30 D 2m μ = 2.95 D 
 
3d μ = 6.25 D 3l μ = 4.12 D
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2.3. Cytotoxicity of 1g, 2b, 2m, 3d, and 3l against L929 Cells 
Since all studied compounds appeared to be more potent than control drug sulfadiazine, the assay 
for the protozoan parasite T. gondii has been expanded to include a preliminary study on their in vitro 
host cell toxicity effects using an MTT assay. From a biological point of view, it is important for the 
studied compounds to inhibit the parasite growth at a low concentration and at the same time show no 
or low toxicity effects on host cells. Otherwise, the activity might be just due to the general toxicity, 
which disqualifies the compound as a drug or lead molecule candidate. Fortunately, from a comparison 
of the cytotoxicity test (CC30, Table 2) results and anti-T. gondii activity tests (Table 1), it can be seen 
clearly that all tested compounds inhibited the parasite growth at non-cytotoxic concentrations in host 
cells. The morphology of normal cells and the morphology of cells cultured with tested compounds are 
presented in Figure S1 in Supplementary Material. 
Table 2. The viability of L929 cells (in % of viable L929 cells) in the concentration range 
of 1g, 2b, 2m, 3d, and 3l between 1 µg/mL and 500 µg/mL ± SD. 
Cmpd. 
No. 
Concentration [µg/mL]  
CC30 [µg/mL] 
500 100 50 10 5 1 
1g 39.76 ± 5.83 * 67.00 ± 11.38 * 79.05 ± 2.89 * 97.32 ± 4.98 99.51 ± 5.16 102.52 ± 2.69 210.04 
2b 30.28 ± 0.86 78.22 ± 1.61 * 84.54 ± 1.43 * 91.93 ± 5.21 * 94.01 ± 1.78 * 95.27 ± 9.52 187.51 
3d 41.45 ± 5.16 * 79.53 ± 5.82 * 90.88 ± 6.71 * 97.51 ± 5.98 99.14 ± 0.82 102.36 ± 3.89 242.56 
3l 48.02 ± 10.12 * 89.55 ± 3.44 * 99.04 ± 10.02 * 95.89 ± 0.39 * 92.87 ± 0.23 * 96.54 ± 0.69 285.52 
2m 80.40 ± 2.74 * 92.17 ± 2.31 * 90.49 ± 2.99 * 94.05 ± 5.13 94.44 ± 2.62 104.05 ± 0.12 >500 
* p < 0.05; To calculate the reduction of viability compared to the untreated blank the Equation was used: 
viability (%) = 100 × sample OD570 (the mean value of the measured optical density of the 1–100 µg/mL 
compounds of the test samples/blank OD570 ( the mean value of the measured optical density of the untreated 
cells). CC30[µg/mL]—represents the concentration of tested compounds that was required for 30% 
proliferation inhibition in vitro. The effect of tested compounds on the cell line L929 (%) was measured using 
MTT assay according to the international standards: ISO 10993-5:2009(E). 
2.4. Antibacterial Activity and Inhibitory Potency against Bacterial Type IIA Topoisomerases 
In our resent papers [23,44] we have reported the antibacterial activity of thirty-one  
4-arylthiosemicarbazides and found that some of tested compounds were effective against the 
reference strains of Gram-positive bacterial species and clinical isolates of Staphylococcus aureus with 
minimal inhibitory concentrations (MICs) in the range of 15.63–62.50 µg/mL. In addition, we have 
also reported two thiosemicarbazide derivatives [45], that is 4-benzoyl-1-(4-methyl-imidazol-5-
yl)carbonylthiosemicarbazide with IC50 at 90 μg/mL and 4-benzoyl-1-(indol-2-yl)carbonyl-
thiosemicarbazide with IC50 at 14 μg/mL, as initial prototypes of a novel class of inhibitors of bacterial 
topoisomerase IV—the enzyme that is essential for proper chromosome segregation and, consequently, 
to the survival of prokaryotic cells [46]. It was reasonable to suppose, therefore, that title compounds 
may also possess antibacterial activity. Thus, in addition to the antitoxoplasmic assays, we also  
tested antibacterial potency of 1g, 2b, and 2m against panel of Gram-positive and Gram-negative 
bacterial strains. The antibacterial screening for compounds 3d and 3l was presented in our  
previous contribution [38] and it was found that both compounds were ineffective against all test 
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microorganisms. Unfortunately, no growth-inhibiting effect on both Gram-positive and Gram negative 
bacterial strains was also observed for compounds 1g, 2b, and 2m even at high concentrations. 
Nevertheless, as the geometry of molecule 1g was similar to that of previously reported initial hits [39] 
(Figure 4), DNA gyrase and topoisomerase IV inhibition tests for 1g were also conducted. No 
inhibitory effect, however, was observed against both bacterial enzymes. 
Figure 4. Overlay of the structures of known S. aureus topoisomerase IV inhibitor (tubes) [39] 
and 4-(4-fluorophenyl)-1-(thiophen-2-yl)carbonylthiosemicarbazide 1g (balls and sticks). 
 
3. Experimental  
3.1. General Information 
All commercial reactants and solvents were purchased from either Sigma-Aldrich ((St. Louis, MS, 
USA) or Lancaster ((Ward Hill, NY, USA) with the highest purity and used without further 
purification. Melting points were determined on a Fischer-Johns block and are uncorrected. Elemental 
analyses were performed by a AMZ-CHX elemental analyzer. IR spectra were recorded in KBr using a 
Specord IR-75 spectrophotometer. 1H-NMR spectra were recorded on a Bruker Avance (300 MHz). 
Analytical thin layer chromatography (TLC) was performed with Merc 60F254 silica gel plates and 
visualized by UV irradiation (254 nm).  
3.2. Chemistry: General Procedure for Synthesis of 1-Substituted-4-arylthiosemicarbazides 
A solution of 0.01 mol of carboxylic acid hydrazide and an equimolar amount of the appropriate 
isothiocyanate in anhydrous EtOH (25 mL) was heated under reflux for 30 min. Next, the solution was 
cooled and the solid formed was filtered off, washed with diethyl ether, dried, and crystallized from 
EtOH. Physicochemical characterizations of 1a, 1c, 1d, 1g, 1k, 1l, 1m, 1n, 2b, 2f, 2i, 3d, 3h, and 3l 
has been presented previously [38,47–52]. The structures of compounds 1b (CAS number 891059-78-2) 
and 1e (CAS number 903081-57-2) are known, however, there is no reference reporting their use or 
preparation or physico-chemical characterization, therefore their data have been included in  
this manuscript. 
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4-(2-Methylphenyl)-1-(thiophen-2-yl)carbonylthiosemicarbazide (1b). Yield: 94%. Mp: 155–157 °C. 
IR (ν, cm−1) 3354, 3337, 3308 (NH), 3084, 1601, 1586, 1527, 1485, 730 (Ar-H), 2922, 1349 (Aliph.), 
1664 (C=O), 1245 (C=S), 775 (C–S). 1H-NMR (DMSO-d6) δH 2.19 (s, 3H, CH3), 7.10–7.23 (m, 5H,  
4 × CHar & CHthiophene), 7.83–7.86 (m, 2H, 2 × CHthiophene), 9.62, 10.55 (2s, 3H, 3 × NH). Anal. Calcd 
for C13H13N3OS2 (291.39): C, 53.58; H, 4.50; N, 14.42. Found: C, 53.72; H, 4.59; N, 14.66. 
4-(3-Methylphenyl)-1-(thiophen-2-yl)carbonylthiosemicarbazide (1e). Yield: 93%. Mp: 188–190 °C. 
IR (ν, cm−1) 3321, 3220 (NH), 3095, 3047, 1625, 1511, 725 (Ar-H), 2916, 1492, 1365 (Aliph.), 1664 
(C=O), 1235 (C=S), 773 (C–S). 1H-NMR (DMSO-d6) δH 2.29 (s, 3H, CH3), 6.96-6.98 (m, 1H, 
CHthiophene), 7.17–7.29 (m, 4H, 2×CHar), 7.84–7.87 (m, 2H, 2 × CHthiophene), 9.68, 9.81, 10.53 (2s, 3H,  
3 × NH). Anal. Calcd for C13H13N3OS2 (291.39): C, 53.58; H, 4.50; N, 14.42. Found: C, 53.53; H, 4.66; 
N, 14.51. 
3.3. Assay in Vitro for Anti-T. gondii Activity 
3.3.1. Animals 
Inbred mice were kept under standard laboratory conventional conditions. All experimental 
procedures were conducted according to guidelines of the 9. Local Ethics Commission for 
Experiments on Animals in Lodz.  
3.3.2. Parasites 
The tachyzoites of T. gondii strain RH – intraspecies type I (ATCC_ Number 50174™) were 
maintained through passages on female C57BL/6 (H-2b) and BALB/c (H-2d) mice with genetically 
determined high and low susceptibility (respectively) to T. gondii infection (10–12 weeks old). 
Tachyzoites washed out from the peritoneum cavity were once expanded in vitro on L929 cells.  
3.3.3. Influence of Thiosemicarbazide Derivatives on T. gondii Proliferation 
L929, (2 × 104 cells/100 µL/well) were grown in complete medium (IMDM) on 96-well plates. 
After 24 h incubation, a medium was removed and then T. gondii RH tachyzoites, suspended in culture 
medium supplemented with 1.0, 5.0, 10.0, 50.0 and 100.0 μg/mL 1,4-disubstituted thiosemicarbazides 
(1g, 2b, 2m, 3d, 3l) and as a control-sulfadiazine, were added (2 × 105 tachyzoites/200 µL/well) to the 
cell monolayers. After subsequent 48 h incubation 1 µCi/well of [3H] uracil (Moravek Biochemicals 
Inc., Brea, CA, USA) was applied to each microculture for further 18–20 h. The amount of the isotope 
incorporated into the parasite nucleic acid pool, corresponding to the parasite growth, was measured by 
liquid scintillation counting with 1450 Microbeta Plus Liquid Scintillation Counter (Wallac Oy, Turku, 
Finland). The cpms of host cells alone (below 250/microculture) were subtracted from cpms of  
T. gondii infected microcultures. 
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3.4. Quantitative Real-Time PCR 
3.4.1. DNA Extraction 
T. gondii genomic DNA was isolated from the tachyzoites of RH strain with Wizard® SV Genomic 
DNA Purification System (Promega, Madison, WI, USA) according to the manufacturer’s instruction. 
The DNA concentration and purity were measured using a NanoPhotometer (Implen, München, 
Germany), while the integrity of the extracted DNA was tested using an ethidium bromide-stained 
agarose gel. DNA was used for the detection and quantitation of T. gondii in analyzed samples and it 
was stored at −20 °C until use. 
3.4.2. Detection in Infected Cells in the Presence of Tested Compounds 
A quantitative real-time PCR (qRT-PCR) assay, targeting B1 gene [53] was performed to detect and 
to quantitate T. gondii in analyzed samples (1g, 2b, 2m, 3d, 3l and sulphadiazine) according to the 
modified protocol of Wahab et al. [54]. The forward primer GCATTGCCCGTCCAAACT, the reverse 
primer AGACTGTACGGAATGGAGACGAA and 5'-Fam-CAACAACTGCTCTAGCG-BHQ-1-3' 
probe were used. Amplification was carried out on a 7900HT real-time PCR system (Applied 
Biosystems, Carlsbad, CA, USA). The reaction mixtures (25 µL) consisted of 1x TaqMan PCR master 
mix supplemented with ROX (Applied Biosystems), 300 nM probe, 900 nM of each primer and 2 µL 
of template DNA. For quantification a standard curve was constructed using 10-fold serial dilutions of 
DNA extracted from a known number of T. gondii. The cycling parameters were: 50 °C for 2 min, initial 
activation at 95 °C for 10 min, and 45 two-step cycles of 95 °C for 15 s and 60 °C for 1 min. All 
samples were analyzed in triplicate. 
3.5. Cytotoxic Assay 
3.5.1. Cell Culture 
Cell line L929 (ATTC® Catalog No. CCL-1, mouse fibroblasts) was routinely cultured in Iscove’s 
modified Dulbecco medium (IMDM, Cytogen, Princeton, NJ, USA), supplemented with 10% (v/v) 
fetal bovine serum (FBS, Sigma), plus 2 mM L-glutamine (Sigma), 100.0 U/mL penicillin (Sigma),  
100.0 μg/mL streptomycin (Sigma), 5 × 10−5 M 2-mercaptoethanol (Sigma) and grown at 37 °C in a  
10% CO2 humidified environment. 
3.5.2. Preparation of Compounds 
Suspensions of the compounds 1g, 2b, 2m, 3d, 3l and sulphadiazine were freshly prepared before 
the cells were exposed, and diluted 1–500 μg/mL with the culture medium (containing 2.5% DMSO). 
Cells treated with 2.5% DMSO-solvent served as a control in each experiment. 
3.5.3. Cell Viability Assay 
The effects of tested compounds on the viability of mouse fibroblasts L929 cells were evaluated 
using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The MTT assay 
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was used according to international standards: ISO 10993-5:2009(E), Biological evaluation of medical 
devices, Part 5: Tests for in vitro cytotoxicity. L929 cells were placed into 96-well plates at a density of 
1.0 × 104/100 μL/well in culture medium and allowed to attach and form a confluent monolayer for 24 h 
before treatment. Afterwards, culture medium in the plates was replaced by 100 μL compounds 
suspension at concentration of 0–500 μg/mL and the cells were exposed for 24 h. Then, 1 mg/mL MTT 
(50 μL/well) was added to each well and incubated at 37 °C, 10% CO2 for 2 h. Mitochondrial 
dehydrogenases of viable cells reduced the yellowish water-soluble MTT to water-insoluble formazan 
crystals, which were solubilized with dimethyl sulfoxide (DMSO). The cell culture medium was 
aspirated cautiously, after which 150 μL DMSO was added to each well and mixed thoroughly. Optical 
density (OD) was read on the ELISA reader (Multiskan EX, Labsystems, Vienna, VA, USA) at 550 nm. 
The results were expressed as percentage viability compared with the treated 2.5% DMSO controls. 
All experiments were performed in triplicate. 
3.6. Antibacterial Assay 
The following microorganisms were used in this study: Staphylococcus aureus (ATCC 25923, 
ATCC 6538, ATCC 29213, NCTC 4163), Staphylococcus epidermidis ATCC 12228, Bacillus subtilis 
ATCC 6633, Bacillus cereus ATCC 11778, Micrococcus luteus (ATCC 9341, ATCC 10240), 
Escherichia coli (ATCC 10538, ATCC 25922, NCTC 8196), Pemphigus vulgaris NCTC 4635, 
Pseudomonas aeruginosa (ATCC 15442, ATCC 27853, NCTC 6749), and Bordetella bronchiseptica 
ATCC 4617. Initially, antibacterial activity of thiosemicarbazide derivatives was screened on the basis 
of growth inhibition zone (giz) utilizing the disc diffusion method, according to the Clinical and 
Laboratory Standards Institute guidelines [55]. For compounds showing the inhibitory effect on the 
growth of tested bacteria, monitored as an appearance of giz, the minimal inhibitory concentrations 
(MICs) were determined using agar dilution method, according to the Clinical and Laboratory 
Standards Institute guidelines [56]. The minimal inhibitory concentrations (MICs) were defined as the 
lowest concentration of the compound preventing growth of the tested microorganism. In both 
methods, recommended Mueller-Hinton II agar medium (Becton Dickinson, Heidelberg, Germany) 
was used. Solutions containing the tested agents were prepared in methanol or DMSO. Ciprofloxacin 
was used as control antimicrobial agent. 
3.7. Inhibition of Bacterial Type IIA Topoisomerases  
3.7.1. Supercoiling Assays 
The assays were performed using S. aureus Gyrase Supercoiling Assay Kits (Inspiralis, Norwich, 
UK). Briefly, supercoiled pBR322 plasmid DNA (0.5 mg) was incubated with 1 unit of gyrase, in the 
dedicated supercoiling assay buffer supplied by the manufacturer, in the presence of varying 
concentrations of the compounds tested. Reactions were carried out at 37 °C for 1 h and then 
terminated by the addition of equal volume of 2 × STOP Buffer (40% sucrose, 100 mM Tris-Cl pH 7.5,  
1 mM EDTA, and 0.5 mg/mL bromophenol blue) and chloroform/isoamyl alcohol. Samples were 
vortexed, centrifuged and run through a 15 cm 1% agarose gel in TAE buffer (40 mM Trisacetate,  
2 mM EDTA) for 3 h at 50 V. Gels were stained with ethidium bromide and visualized under UV light. 
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3.7.2. Decatenation Assays 
The assays were performed using S. aureus topoisomerase IV decatenation kits (Inspiralis). 
Interlinked kDNA substrate (0.5 mg) was incubated with 1 unit of topoisomerase IV (Inspiralis), in the 
dedicated decatenation assay buffer supplied by the manufacturer, in the presence of varying 
concentrations of the compounds tested. Reactions were carried out at 37 °C for 1 h and then 
terminated by the addition of equal volume of 2× STOP Buffer (40% sucrose, 100 mM Tris-Cl pH 7.5, 
1 mM EDTA, 0.5 mg/mL bromophenol blue) and chloroform/isoamyl alcohol. Samples were vortexed, 
centrifuged and run through a 15 cm 1% agarose gel in TAE buffer for 1.5 h at 80 V. Gels were stained 
with ethidium bromide and visualized under UV light. The concentrations of the inhibitor that 
prevented 50% of the kinetoplast DNA from being converted into decatenated minicircles (IC50 values) 
were determined by plotting the results obtained from the densytometric analyses of the gel images 
using Quantity One software (BioRad, Hercules, CA, USA). 
3.8. Data Analysis 
The results of experiments (3.2. and 3.4.) were shown as a mean arithmetic values from 6–18 
repeats (2–6 experiments) and were analyzed for statistical significance with the Statistica PL 5.0 
software using the Mann-Whitney U test. During statistical verification, significance levels of * p < 0.05 
were considered. 
3.9. Computational Details 
Conformational search was performed using the Amber force field as implemented in HyperChem 
8.0.3. [57] and default convergence criteria. For the most stable conformers population analysis was 
carried out using the Merz-Kollman scheme [58] at the HF/6-31G theory level with the use of the 
Gaussian package [59]. 
3.10. Docking Studies 
The docking simulations were performed using the FlexX docking module of the LeadIT 
environment as implemented in the BioSolveITprogram using models of following enzymes: purine 
nucleoside phosphorylase (PNP; PDB ID: 3MB8 ), adenosine kinase ([EC.2.7.1.20]; PDB ID: 1LII), 
calcium-dependent protein kinase-1 (TgCDPK1; PDB ID: 4M84), 1-deoxy-D-xylulose-5-phosphate 
reductoisomerase (DXR; PDB ID: 3AU9), enoyl reductase (TgENR; PDB ID: 2o2s), complexed with 
their reference ligands. The active sites were defined to include all atoms within 10 Å radius of the 
native ligands. To validate the docking protocol, ligands co-crystallized with the proteins were initially 
docked into the crystal structure of the appropriate enzymes; the best conformations obtained were 
practically identical with the experimental ones. Subsequently, studied compounds were docked using 
the same docking parameters. The first 100 top ranked docking poses were saved for each docking run. 
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4. Conclusions 
In conclusion, a series of thiosemicarbazides was evaluated in vitro for inhibition of T. gondii 
proliferation and host cell cytotoxicity. All studied compounds displayed significant and reproducible 
anti-parasitic effects at concentrations that were non-toxic toward the host cells, with experimentally 
determined IC50 values at least twice (or even fifteen times) higher than that of sulfadiazine. DFT 
calculations seem to indicate that the activity depends on the bimodal partial negative charge 
developed on the carbonyl oxygen and another moiety on the same side of the molecule. Since the 
number of compounds studied here is limited, the above observations can be treated as initial 
suggestions and will be used as a guide for synthesis of other compounds in further studies. 
Supplementary Materials 
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/19/7/9926/s1. 
Acknowledgments 
The project was partially funded by the National Science Centre (decision number: 
2012/05/D/NZ7/02278). We are thankful to Artur Ruszczak for the technical assistance. 
Author Contributions 
Katarzyna Dzitko: Selection of the research theme and the range of studies, the managing of the 
research project which included the studies described in the manuscript and essential guidance for their 
correct execution, participation in the discussion of the obtained results, contribution in writing and 
editing of this manuscript, and correspondence with editorial office. Agata Paneth: Synthesis of studied 
thiosemicarbazides and participation in the discussion of the results obtained from theoretical 
calculations. Tomasz Plech: Perform docking simulations. Jakub Pawełczyk: Perform qRT-PCR assay. 
Joanna Stefańska: Perform antibacterial assay. Paweł Stączek: Perform enzymatic assay. Piotr Paneth: 
Perform theoretical calculations. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Petersen, E.; Dubey, J.P. Biology of Toxoplasma gondii. In Toxoplasmosis: A Comprehensive 
Clinical Guide; Joynson, D.H.M., Wreghitt, T., Eds.; Cambridge University Press: Cambridge, 
UK, 2001; pp. 1–49. 
2. Robert-Gangneux, F.; Dardé, M.L. Epidemiology of and diagnostic strategies for toxoplasmosis. 
Clin. Microbiol. Rev. 2012, 25, 264–296.  
3. Contini, C. Clinical and diagnostic management of toxoplasmosis in the immunocompromised 
patient. Parassitologia 2008, 50, 45–50.  
Molecules 2014, 19 9940 
 
4. Ambroise-Thomas, P.; Pelloux, H. Toxoplasmosis-congenital and in immunocompromised 
patients: A parallel. Parasitol. Today 1993, 9, 61–63. 
5. Ferreira, M.S.; Borges, A.S. Some aspects of protozoan infections in immunocompromised 
patients-a review. Mem. Inst. Oswaldo. Cruz. 2002, 97, 443–457. 
6. Bosch-Driessen, L.E.; Berendschot, T.T.; Ongkosuwito, J.V.; Rothova, A. Ocular toxoplasmosis: 
clinical features and prognosis of 154 patients. Ophthalmology 2002, 109, 869–878. 
7. Paquet, C.; Yudin, M.H. Toxoplasmosis in pregnancy: Prevention, screening, and treatment.  
J. Obstet. Gynaecol. Can. 2013, 35, 78–79. 
8. Wallon, M.; Kodjikian, L.; Binquet, C.; Garweg, J.; Fleury, J.; Quantin, C.; Peyron, F. Long-term 
ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004, 113, 1567–1572. 
9. Silveira, C.; Belfort, R.; Muccioli, C.; Holland, G.N.; Victora, C.G.; Horta, B.L.; Fei, Y.; 
Nussenblatt, R.B. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment 
on recurrences of toxoplasmic retinochoroiditis. Am. J. Ophthalmol. 2002, 134, 41–46.  
10. Yazici, A.; Ozdal, P.C.; Taskintuna, I.; Kavuncu, S.; Koklu, G. Trimethoprim/Sulfamethoxazole 
and azithromycin combination therapy for ocular toxoplasmosis. Ocul. Immunol. Inflamm. 2009, 
17, 289–291. 
11. Dibbern, D.; Montanaro, A. Allergies to sulfonamide antibiotics and sulfur-containing drugs.  
Ann. Allerg. Asthma Immunol. 2008, 100, 91–101. 
12. Kongsaengdao, S.; Samintarapanya, K.; Oranratnachai, K.; Prapakarn, W.; Apichartpiyakul, C. 
Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus 
sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients. J. Int. Assoc. 
Physicians AIDS Care 2008, 7, 11–16. 
13. McLeod, R.; Khan, A.R.; Noble, G.A.; Latkany, P.; Jalbrzikowski, J.; Boyer, K. Severe 
sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. 
Pediatr. Infect. Dis. J. 2006, 25, 270–272. 
14. Aspinall, T.V.; Joynson, D.H.; Guy, E.; Hyde, J.E.; Sims, P.F. The molecular basis of sulfonamide 
resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis.  
J. Infect. Dis. 2002, 185, 1637–1643. 
15. Remington, J.S.; McLeod, R.; Thulliez, P.; Desmonts, G. Toxoplasmosis. In Infectious Diseases 
of the Fetus and Newborn Infant, 7th ed.; Remington, J., Klein, J., Eds.; Saunders: Philadelphia, 
PA, USA, 2011. 
16. Degerli, K.; Kilimcioglu, A.A.; Kurt, Ö.; Tamay, T.; Ozbilgin, A. Efficacy of azithromycin in a 
murine toxoplasmosis model, employing a Toxoplasma gondii strain from Turkey. Acta Trop. 
2003, 88, 45–50. 
17. Kijlstra, A.; Jongert, E. Toxoplasma-safe meat: Close to reality? Trends Parasitol. 2009, 25, 18–22. 
18. Dial, S.; Kezouh, A.; Dascal, A.; Barkun, A.; Suissa, S. Patterns of antibiotic use and risk of 
hospital admission because of Clostridium difficile infection. CMAJ 2008, 179, 767–772. 
19. Megged, O.; Shalit, I.; Yaniv, I.; Stein, J.; Fisher, S.; Levy, I. Breakthrough cerebral 
toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell 
transplantation. Pediatr. Transplant. 2008, 12, 902–905. 
20. Montoya, J.; Remington, J. Management of Toxoplasma gondii infection during pregnancy.  
Clin. Infect. Dis. 2008, 47, 554–566. 
Molecules 2014, 19 9941 
 
21. Liesen, A.P.; de Aquino, T.M.; Carvalho, C.S.; Lima, V.T.; de Araújo, J.M.; de Lima, J.G.;  
de Faria, A.R.; de Melo, E.J.T.; Alves, A.J.; Alves, E.W.; et al. Synthesis and evaluation of  
anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 
1,3,4-thiadiazoles. Eur. J. Med. Chem. 2010, 45, 3685–3691. 
22. Siwek, A.; Świderek, K.; Jankowski, S. Problems with molecular mechanics implementations on 
the example of 4-benzoyl-1-(4-methyl-imidazol-5-yl)-carbonyl-thiosemicarbazide. J. Mol. Model. 
2012, 18, 843–849. 
23. Plech, T.; Wujec, M.; Siwek, A.; Kosikowska, U.; Malm, A. Synthesis and antimicrobial activity 
of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety. Eur. J. 
Med. Chem. 2011, 46, 241–248. 
24. Derouin, F.; Chastang, C. In vitro effects of folate inhibitors on Toxoplasma gondii. Antimicrob. 
Agents Chemother. 1989, 33, 1753–1759. 
25. Meneceur, P.; Bouldouyre, M.A.; Aubert, D.; Villena, I.; Menotti, J.; Sauvage, V.; Garin, J.F.; 
Derouin, F. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to 
pyrimethamine, sulfadiazine, and atovaquone. Antimicrob. Agents Chemother. 2008, 52, 1269–1277.  
26. Doliwa, C.; Escotte-Binet, S.; Aubert, D.; Velard, F.; Schmid, A.; Geers, R.; Villena, I. Induction 
of sulfadiazine resistance in vitro in Toxoplasma gondii. Exp. Parasitol. 2013, 133, 131–136.  
27. De Oliveira, T.C.; Silva, D.A.; Rostkowska, C.; Béla, S.R.; Ferro, E.A.; Magalhães, P.M.;  
Mineo, J.R. Toxoplasma gondii: Effects of Artemisia annua L. on susceptibility to infection in 
experimental models in vitro and in vivo. Exp. Parasitol. 2009, 122, 233–241.  
28. Van der Ven, A.J.; Schoondermark-van de Ven, E.M.; Camps, W.; Melchers, W.J.; Koopmans, P.P.; 
van der Meer, J.W.; Galama, J.M. Anti-toxoplasma effect of pyrimethamine, trimethoprim and 
sulphonamides alone and in combination: Implications for therapy. J. Antimicrob. Chemother. 
1996, 38, 75–80. 
29. Jin, C.; Jung, S.Y.; Kim, S.Y.; Song, H.O.; Park, H. Simple and efficient model systems of 
screening anti-Toxoplasma drugs in vitro. Expert. Opin. Drug Discov. 2012, 7, 195–205. 
30. Alvarez, F.; Ghérardi, A.; Nebois, P.; Sarciron, M.E.; Pétavy, A.F.; Walchshofer, N. 
Benzimidazole-4,7-diones as inhibitors of protozoal (Toxoplasma gondii) purine nucleoside 
phosphorylase. Bioorg. Med. Chem. Lett. 2002, 12, 977–979. 
31. Kim, Y.A.; Rawal, R.K.; Yoo, J.; Sharon, A.; Jha, A.K.; Chu, C.K.; Rais, R.H.; Al Safarjalani, O.N.; 
Naguib, F.N.M.; Kouni, M.H. Structure-activity relationships of carbocyclic 6-benzylthioinosine 
analogues as subversive substrates of Toxoplasma gondii adenosine kinase. Bioorg. Med. Chem. 
2010, 18, 3403–3412. 
32. Rosowsky, A.; Chen, H.; Fua, H.; Queener, S.F. Synthesis of new 2,4-diaminopyrido[2,3-
d]pyrimidine and 2,4-diaminopyrrolo[2,3-d]pyrimidine inhibitors of pneumocystis carinii, 
Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase. Bioorg. Med. Chem. 
2003, 11, 59–67. 
33. Rosowsky, A.; Forsch, R.A.; Queener, S.F. 2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of 
dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem. 1995, 
38, 2615–2620. 
Molecules 2014, 19 9942 
 
34. Ojo, K.K.; Larson, E.T.; Keyloun, K.R.; Castaneda, L.J.; de Rocher, A.E.; Inampudi, K.K.;  
Kim, J.E.; Arakaki, T.L.; Murphy, R.C.; Zhang, L.; et al. Toxoplasma gondii calcium-dependent 
protein kinase 1 is a target for selective kinase inhibitors. Nat. Struct. Mol. Biol. 2010, 17, 602–607. 
35. Murphy, R.C.; Ojo, K.K.; Larson, E.T.; Castellanos-Gonzalez, A.; Perera, B.G.K.; Keyloun, K.R.; 
Kim, J.E.; Bhandari, J.G.; Muller, N.R.; Verlinde, C.L.M.J.; et al. Discovery of potent and selective 
inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondii.  
ACS Med. Chem. Lett. 2010, 1, 331–335. 
36. Sugi, T.; Kato, K.; Kobayashi, K.; Watanabe, S.; Kurokawa, H.; Gong, H.; Pandey, K.; Takemae, H.; 
Akashi, H. Use of the kinase inhibitor analog 1NM-PP1 reveals a role for Toxoplasma gondii 
CDPK1 in the invasion step. Eukaryot. Cell 2010, 9, 667–670.  
37. Zhang, Z.; Ojo, K.K.; Johnson, S.M.; Larson, E.T.; He, P.; Geiger, J.A.; Castellanos-Gonzalez, A.; 
White, A.C., Jr.; Parsons, M.; Merritt, E.A.; et al. Benzoylbenzimidazole-based selective 
inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein 
kinase-1. Bioorg. Med. Chem. Lett. 2012, 22, 5264–5267. 
38. Cai, G.; Deng, L.; Xue, J.; Moreno, S.N.J.; Striepen, B.; Song, Y. Expression, characterization 
and inhibition of Toxoplasma gondii 1-deoxy-D-xylulose-5-phosphate reductoisomerase. Bioorg. 
Med. Chem. Lett. 2013, 23, 2158–2161. 
39. Hunter, W.N. The non-mevalonate pathway of isoprenoid precursor biosynthesis. J. Biol. Chem. 
2007, 282, 21573–21577.  
40. Singh, N.; Cheve, G.; Avery, M.A.; McCurdy, C.R. Targeting the methyl erythritol phosphate 
(MEP) pathway for novel antimalarial, antibacterial and herbicidal drug discovery: Inhibition of 
1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme. Curr. Pharm. Des. 2007, 13, 
1161–1177. 
41. Cheng, G.; Muench, S.P.; Zhou, Y.; Afanador, G.A.; Mui, E.J.; Fomovska, A.; Lai, B.S.; Prigge, S.T.; 
Woods, S.; Roberts, C.W; et al. Design, synthesis, and biological activity of diaryl ether inhibitors 
of Toxoplasma gondii enoyl reductase. Bioorg. Med. Chem. Lett. 2013, 23, 2035–2043. 
42. Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FLEXX incremental construction 
algorithm for protein-ligand docking. Proteins 1999, 37, 228–241. 
43. LeadIT, version 2.1.0; BioSolveIT GmbH: St. Augustin, Germany, 2012. 
44. Siwek, A.; Stączek, P.; Stefańska, J. Synthesis and structure-activity relationship studies of  
4-arylthiosemicarbazides as topoisomerase IV inhibitors with Gram-positive antibacterial activity. 
Search for molecular basis of antibacterial activity of thiosemicarbazides. Eur. J. Med. Chem. 
2011, 46, 5717–5726. 
45. Siwek, A.; Stączek, P.; Wujec, M.; Stefańska, J.; Kosikowska, U.; Malm, A.; Jankowski, S.; 
Paneth, P. Biological and docking studies of topoisomerase IV inhibition by thiosemicarbazides.  
J. Mol. Model. 2011, 17, 2297–2303. 
46. Andersonm, V.E.; Gootz, T.D.; Osheroff, N. Topoisomerase IV Catalysis and the Mechanism of 
Quinolone Action. J. Biol. Chem. 1998, 273, 17879–17885. 
47. Nath, T.G.S.; Husain, S.; Srinivasan, V.R. Synthesis and reactivity of 4,5-disubstituted 3-chloro-
1,2,4-triazoles and their methylsulfonyl analogs. Indian J. Chem. Sec. B 1977, 15B, 341–346. 
Molecules 2014, 19 9943 
 
48. Siwek, A.; Stefańska, J.; Dzitko, K.; Ruszczak, A. Antifungal effect of 4-arylthiosemicarbazides 
against Candida species. Search for molecular basis of antifungal activity of thiosemicarbazide 
derivatives. J. Mol. Model. 2012, 18, 4159–4170. 
49. Chen, H.-L.; Guo, Z.-F.; Lu, Z.-L. Controlling ion-sensing specificity of N-amidothioureas: From 
anion-selective sensors to highly Zn2+-selective sensors by tuning electronic effects. Org. Lett. 
2012, 14, 5070–5073. 
50. Goldfarb, D.S. Method Using Lifespan-Altering Compounds For Altering The Lifespan Of 
Eukaryotic Organisms, and Screening for Such Compounds. U.S. Patent US20090163545 A1, 25 
June 2009. 
51. Siwek, A.; Wujec, M.; Dobosz, M.; Jagiello-Wojtowicz, E.; Kleinrok, A.; Chodkowska, A.; 
Paneth, P. Chemical and pharmacological properties of 3-(thiophen-2-yl)-4-substituted-Δ2-1,2,4-
triazoline-5-thiones. Phosphorus Sulfur 2008, 183, 2669–2677. 
52. Siwek, A.; Wujec, M.; Stefanska, J.; Paneth, P. Antimicrobial properties of 4-aryl-3-(2-methyl-
furan-3-yl)-Δ2-1,2,4-triazoline-5-thiones. Phosphorus Sulfur 2009, 184, 3149–3159. 
53. Burg, J.L.; Grover, C.M.; Pouletty, P.; Boothroyd, J.C. Direct and sensitive detection of a 
pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction. J. Clin. Microbiol. 
1989, 27, 1787–1792. 
54. Wahab, T.; Edvinsson, B.; Palm, D.; Lindh, J. Comparison of the AF146527 and B1 repeated 
elements, two real-time PCR targets used for detection of Toxoplasma gondii. J. Clin. Microbiol. 
2010, 48, 591–592. 
55. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial disc 
Susceptibility Tests, Approved Standard M2-A9; Clinical and Laboratory Standards Institute: 
Wayne, PA, USA, 2006. 
56. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility 
Tests for Bacteria that Grow Aerobically, Approved Standard M7-A7; Clinical and Laboratory 
Standards Institute: Wayne, PA, USA, 2006. 
57. Hyperchem, version 8.0.3; HyperCube Inc.: Gainsville, FL, USA, 2007. 
58. Singh, U.C.; Kollman, P.A. An approach to computing electrostatic charges for molecules.  
J. Comp. Chem. 1984, 5, 129–145. 
59. Frisch, M.J. Gaussian 09, revision A.02. Gaussian Inc.: Wallingford, CT, USA, 2009. 
Sample Availability: Samples of the tested compounds are available from the authors.  
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
